Ginkgo Bioworks Holdings Inc DNA shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc CRON, announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids.
Using Ginkgo's platform for organism design and development, Cronos says the company has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC.
Cronos added that, launched in 2018 with the goal of accessing rare molecules in the cannabis plant to create innovative and differentiated products that would otherwise be cost-prohibitive, the partnership between Cronos and Ginkgo aims to produce cultured cannabinoids at an industrial scale.
See Also: So Does Tesla Or Lucid Make The Cooler-Looking Electric Vehicle? Over 60% Say...
Ginkgo Bioworks is building a platform to enable customers to program cells as easy to program computers.
According to data from Benzinga Pro, Ginkgo Bioworks has a 52-week high of $15.86 and a 52-week low of $2.09.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
